Nuwellis Inc vs Under Armour Inc Class A — how do they compare? Nuwellis Inc trades at $0.69 (market cap $2.20M), while Under Armour Inc Class A trades at $4.93 (market cap $2.07B). The key difference: Under Armour Inc Class A is far larger — about 940.9× Nuwellis Inc's market cap, and Under Armour Inc Class A is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Under Armour Inc Class A for 99 Days on average.
| NUWE | UAA | |
|---|---|---|
Market Cap | $2.20M | $2.07B |
Volume | 121,544 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $146.65 | $8.14 |
52-Week Low | $0.68 | $4.17 |
Typical Hold Time | 26 Days | 99 Days |
Enterprise Value | -$1.52M | $3.05B |
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Under Armour (UAA) trades at $4.93, up 2.28% on the day, with a mixed technical outlook showing a bullish moving average signal but a neutral oscillator stance. The company reported a net loss of $201.27M in 2025, with revenue declining to $5.16B, though recent quarterly earnings have beaten expectations. Analyst consensus is a 'Hold' with a $5.79 price target, while news highlights the company's focus on product simplification and margin improvement amid softer demand.
The outlook remains challenging due to persistent revenue weakness and negative profitability, but cost discipline and international growth offer potential stabilization. Key risks include execution of the turnaround plan and competitive pressures. The stock presents a speculative opportunity for investors betting on a successful brand transformation, but requires careful risk assessment given the current financial headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →